Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001‑35403 Verastem, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdic ...

1 | --- | --- | --- | --- | |------------------------------------------|-------|----------------------------------------------|--------------------------------------------------------------------------------------------------------| | | | | | | | | | | | | | Addressing RAS Pathway Blockade & Resistance | | | | | | VS-6766 & Defactinib Combination Data in KRAS Mutant Solid Tumors Investor Conference Call and Webcast | | | | | | | PROPERTY OF VERASTEM, INC. NASDAQ: VSTM | | | April 27, 2020 | Speakers 805 Ver ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35403 Verastem, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001‑35403 Verastem, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other juri ...

Verastem, Inc. (NASDAQ:VSTM) Q3 2019 Earnings Conference Call October 29, 2019 4:30 PM ET Company Participants John Doyle - Vice President of Investor Relations & Finance Brian Stuglik - Chief Executive Officer Dan Paterson - President & Chief Operating Officer Rob Gagnon - Chief Financial & Business Officer Conference Call Participants Emma Nealon - Cantor Fitzgerald Jake Colby - BTIG Swayampakula Ramakanth - H.C. Wainwright Matthew Cross - Jones Trading Operator Good afternoon and welcome to the Verastem ...

Verastem, Inc. (NASDAQ:VSTM) Q2 2019 Earnings Conference Call August 1, 2019 4:30 PM ET Company Participants John Doyle - Vice President of Investor Relations & Finance Brian Stuglik - Chief Executive Officer Dan Paterson - President & Chief Operating Officer Rob Gagnon - Chief Financial & Business Officer Conference Call Participants Alethia Young - Cantor Fitzgerald Bert Hazlett - BTIG George Zavoico - B. Riley FBR Matthew Cross - Jones Trading Operator Good afternoon, and welcome to the Verastem Oncology ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001‑35403 Verastem, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdict ...

Verastem, Inc. (NASDAQ:VSTM) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants John Doyle - VP, IR Robert Forrester - President, CEO & Director Joseph Lobacki - EVP & Chief Commercial Officer Daniel Paterson - COO Robert Gagnon - CFO Conference Call Participants James Colby - BTIG Sean Lee - H.C. Wainwright & Co. George Zavoico - B. Riley FBR, Inc. Matthew Cross - JonesTrading Institutional Services Operator Good afternoon, and welcome to the Verastem Oncology Investor Conference ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001‑35403 Verastem, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdic ...

Verastem, Inc (NASDAQ:VSTM) Q4 2019 Results Earnings Conference Call March 12, 2019 4:30 PM ET Company Participants Robert Forrester - CEO Rob Gagnon - Chief Financial Officer Joseph Lobacki - Chief Commercial Officer Dan Paterson - Chief Operating Officer Conference Call Participants Erin Cox - Senior Director of Investor Relations & Corporate Communications Jake Colby - BTIG Matthew Cross - Jones Trading Swayampaukula Ramakanth - H.C. Wainwright George Zavoico - B. Riley FBR Operator Good afternoon, an ...